T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Varex Imaging
VREX
$780M
| $207K | ﹤0.01% |
+11,382
| New | +$209K |
|
2602
RE/MAX Holdings
RMAX
$265M
| $206K | ﹤0.01% |
23,443
+5,390
| +30% | +$52K |
|
|
EU
2603
enCore Energy
EU
$221M
| $205K | ﹤0.01% |
46,585
+8,954
| +24% | +$37.9K |
|
2604
MarineMax
HZO
$1.15B
| $205K | ﹤0.01% |
6,158
+924
| +18% | +$29.6K |
|
2605
The ONE Group
STKS
$56.8M
| $205K | ﹤0.01% |
36,795
+285
| +0.8% | +$1.25K |
|
|
LUCK
2606
Lucky Strike Entertainment
LUCK
$930M
| $205K | ﹤0.01% |
14,953
+978
| +7% | +$12.6K |
|
|
ACCD
2607
DELISTED
Accolade Inc
ACCD
| $205K | ﹤0.01% |
19,540
+2,586
| +15% | +$29.4K |
|
|
MURA
2608
DELISTED
Mural Oncology
MURA
| $204K | ﹤0.01% |
41,592
+15,600
| +60% | +$75.7K |
|
|
CDMO
2609
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $204K | ﹤0.01% |
30,299
+1,649
| +6% | +$11.3K |
|
|
DX
2610
Dynex Capital
DX
$3.23B
| $203K | ﹤0.01% |
16,259
+2,134
| +15% | +$26.5K |
|
2611
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.5B
| $203K | ﹤0.01% |
+2,200
| New | +$196K |
|
2612
Genie Energy
GNE
$386M
| $202K | ﹤0.01% |
13,359
+1,002
| +8% | +$19.2K |
|
2613
Merchants Bancorp
MBIN
$2.54B
| $202K | ﹤0.01% |
+4,663
| New | +$195K |
|
|
ATXS
2614
DELISTED
Astria Therapeutics
ATXS
| $200K | ﹤0.01% |
+14,203
| New | +$177K |
|
2615
Phibro Animal Health
PAHC
$1.38B
| $200K | ﹤0.01% |
15,393
+1,063
| +7% | +$12.7K |
|
2616
Aehr Test Systems
AEHR
$4.02B
| $199K | ﹤0.01% |
16,018
+961
| +6% | +$16K |
|
2617
AngioDynamics
ANGO
$647M
| $199K | ﹤0.01% |
33,772
+2,821
| +9% | +$16.8K |
|
2618
Life Time Group Holdings
LTH
$9.9B
| $199K | ﹤0.01% |
12,769
+1,866
| +17% | +$25.9K |
|
2619
GrowGeneration
GRWG
$108M
| $198K | ﹤0.01% |
69,104
+22,269
| +48% | +$51.4K |
|
2620
Ardmore Shipping
ASC
$707M
| $196K | ﹤0.01% |
11,934
+1,634
| +16% | +$26K |
|
2621
Aurinia Pharmaceuticals
AUPH
$2.02B
| $196K | ﹤0.01% |
38,952
+5,079
| +15% | +$34.5K |
|
|
VISN
2622
Vistance Networks Inc
VISN
$2.62B
| $196K | ﹤0.01% |
149,227
-371,219
| -71% | -$731K |
|
2623
Pangaea Logistics
PANL
$496M
| $196K | ﹤0.01% |
27,998
+9,352
| +50% | +$76.6K |
|
2624
Senseonics Holdings Inc
SENS
$409M
| $196K | ﹤0.01% |
18,360
+2,550
| +16% | +$29.6K |
|
2625
Cardiff Oncology
CRDF
$76.6M
| $195K | ﹤0.01% |
36,500
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.